➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Colorcon
Dow
Harvard Business School
AstraZeneca

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

NOCDURNA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Nocdurna patents expire, and what generic alternatives are available?

Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and thirty-four patent family members in thirty-three countries.

The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Nocdurna

A generic version of NOCDURNA was approved as desmopressin acetate by TEVA PHARMS USA on October 15th, 1997.

  Start Trial

Drug patent expirations by year for NOCDURNA
Drug Prices for NOCDURNA

See drug prices for NOCDURNA

Recent Clinical Trials for NOCDURNA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ferring PharmaceuticalsPhase 2

See all NOCDURNA clinical trials

US Patents and Regulatory Information for NOCDURNA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for NOCDURNA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3225249 300983 Netherlands   Start Trial PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622 C02712622/01 Switzerland   Start Trial PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
3225249 CA 2019 00023 Denmark   Start Trial PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
2712622 122017000006 Germany   Start Trial PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
2712622 PA2017001,C2712622 Lithuania   Start Trial PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008
2712622 LUC00015 Luxembourg   Start Trial PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Colorcon
Dow
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.